Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Eur Radiol. 2015 Mar 29;25(9):2665–2672. doi: 10.1007/s00330-015-3688-1

Fig. 1.

Fig. 1

Fig. 1

Fig. 1

Fig. 1

Fig. 1

Fig. 1

a-f: Sixty-eight-year-old man with histopathologically-proven prostate cancer (Gleason score 4+4) who had MRI examinations before (a-c) and after the start (d-f) of androgen-deprivation therapy: (a/d) T2-weighted images, (b/e) ADC maps (b = 1000 s/mm2), (c/f) T1-weighted dynamic contrast-enhanced MR images.